Sunday, December 7, 2014


Common name: Pazopanib; Pazopanib hydrochloride; Votrient; GW786034; GW-786034; GW 786034
Trademarks:  Votrient
Molecular Formula: C21H23N7O2S
CAS Registry Number: 444731-52-6; 635702-64-6 (mono HCl)
CAS Name: 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Molecular Weight: 437.517
Activity:  Antineoplastic; Tyrosine Kinase Inhibitors, Protein Kinase Inhibitors; Renal Cell Carcinoma Therpay; Soft Tissue Sarcoma Therapy

Pazopanib synthesis: WO2003106416A2 (same appears in Drug Future 2006, 31, 7, 585-589)

Pazopanib synthesis: J Med Chem 2008, 51, 4632-4640 (same appears in Beilstein J Org Chem 2011, 7, 442–495)

Orange Book says for Pazopanib:

Patent US7105530 Issued on:2009-10-19 Valid till:2023-10-19
Patent US7262203 Issued on:2009-10-19 Valid till:2021-12-19
Patent US8114885 Issued on:2009-10-19 Valid till:2021-12-19

1. Boloor, A.; et. al. Pyrimidineamines as angiogenesis modulators. US7105530B2
2. Boloor, A.; Harris, P. A.; et. al. Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor. J Med Chem 2008, 51(15), 4632–4640.
3. Bhanushali, D. S.; et. al. Compositions and processes. WO2011050159A1
4. Boloor, A.; et. al.  Chemical Process. WO2003106416A2
5. Pandite, A. M.; et. al. Cancer treatment method. WO2007064753A2